ArticleBasic research in cardiology2025
Sonogenetic neuromodulation prevents post-myocardial infarction malignant arrhythmia and cardiac remodeling through the brain-heart circuit.
Article in Basic research in cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Rebooting the Dialogue: Neuromodulation for Immune-Driven Brain-Body Interactions in Post-stroke Emotional Disorders.Neuroscience bulletin · 2026Article
- Focused ultrasound for cellular mechanoactivation and nanomedicine delivery in cancer.Biomedical microdevices · 2026Review
- Ultrasound-activated dual-targeted liposomes for visualized precise neuromodulation against myocardial ischemia-reperfusion injury.Materials today. Bio · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Sympathetic hyperactivation within the paraventricular nucleus (PVN) exacerbates post-myocardial infarction (MI) malignant ventricular arrhythmias (VAs) and cardiac remodeling. Sonogenetics is an emerging reversible neuromodulation, which might achieve precise spatio-temporal controllability over targeted neurons. However, the current sonogenetic neuromodulation (SGN) strategies are mainly designed to facilitate neuronal activation, and experimental evidence supporting neuronal inhibition remains elusive. In the current study, we conducted the first inhibitory sonogenetic neuromodulation system by the mechanosensitive ion channel named TWIK-related arachidonic acid-activated K
Indexed as
Identifiers
40632283What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.